NMN and NR for Adolescents (Ages 12 to 17): What Happens at the Transition to Adult Care

What Are NMN and NR, and Why Do They Matter for NAD+ Biology?

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are two orally bioavailable precursors that the body converts into nicotinamide adenine dinucleotide (NAD+). NAD+ is a coenzyme required for mitochondrial energy metabolism, DNA repair through PARP enzymes, and sirtuin-mediated gene regulation. Without adequate NAD+, these processes slow down.

The NAD+ Decline Story

The commercial narrative around NAD+ precursors rests on a well-documented biological observation: tissue NAD+ concentrations fall with age. A 2012 paper by Gomes and colleagues, published in Cell Metabolism, showed that NAD+ levels in mouse skeletal muscle dropped roughly 50% between young adulthood and middle age, and that NMN supplementation partially restored them (Gomes et al., 2013). Human data support a similar trajectory, though the magnitude varies by tissue and measurement method.

Why Adolescents Are a Different Population

Adolescents ages 12 to 17 are not simply small adults. NAD+ levels at this life stage are near their physiological peak. The cellular machinery for NAD+ biosynthesis, including the rate-limiting enzyme NAMPT (nicotinamide phosphoribosyltransferase), is robustly expressed in healthy young tissue. That biological context matters when evaluating whether supplementation serves any purpose in this age group.

Separately, adolescence involves active hormonal shifts, ongoing neurodevelopment, and significant variation in body weight and renal clearance. Any exogenous compound that interacts with energy metabolism or sirtuin signaling could, in theory, produce effects that differ from what adult trials have measured. No trial has tested this. The honest answer is that the effect profile in 12-to-17-year-olds is unknown.

Is There Any Clinical Evidence Specifically in Adolescents?

No. As of early 2025, a search of PubMed and ClinicalTrials.gov returns zero published randomized controlled trials testing NMN or NR in participants under 18. This is not a minor gap. It means every dosing estimate, every safety assumption, and every efficacy claim applied to adolescents is extrapolated from adult data or animal models.

What the Adult Trial Field Looks Like

The best available adult evidence comes from a small set of short-duration trials:

• NR (CHROMADEX-sponsored): Trammell and colleagues (2016, N=12) showed that oral NR 1,000 mg/day raised whole-blood NAD+ by approximately 2.7-fold compared to baseline in healthy adults over 7 days (Trammell et al., 2016).
• NMN (Yoshino et al., 2021): A 10-week, double-blind, placebo-controlled trial (N=25 postmenopausal women with prediabetes) found that NMN 250 mg/day improved skeletal muscle insulin signaling and gene expression without significant adverse events (Yoshino et al., 2021).
• NMN safety in older adults: Liao and colleagues (2021, N=66, ages 40 to 65) tested NMN 300 mg/day for 60 days and reported no serious adverse events and no clinically significant changes in liver enzymes, kidney function, or hematological parameters (Liao et al., 2021).

These trials inform the adult conversation. They do not inform the adolescent one.

The Informed-Consent Problem

Because no adolescent-specific safety data exist, obtaining truly informed consent from a minor (or assent, with parental consent) for NMN or NR is difficult. A clinician cannot quote a pediatric adverse-event rate because none has been measured. This is one reason HealthRX's medical team does not prescribe or recommend NMN or NR to patients under 18 outside of a formal research protocol.

FDA Regulatory Status and Why It Matters for Teens

NMN and NR are sold in the United States as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA) of 1994. The FDA does not require pre-market efficacy or safety testing for dietary supplements. However, the FDA issued a warning letter in 2022 clarifying that NMN cannot be lawfully marketed as a dietary supplement because it was first studied as a drug under an Investigational New Drug (IND) application, which triggers the drug-exclusion clause in DSHEA (FDA, 2022, Dietary Supplement Ingredient Advisory List).

This regulatory nuance has practical consequences for adolescent patients and their families. Products containing NMN exist in a legally gray zone. Quality control standards that apply to prescription drugs, including batch testing and purity verification, do not apply here. Third-party certification (NSF International, USP, or Informed Sport) offers partial assurance but does not substitute for FDA oversight.

NR, by contrast, has Generally Recognized As Safe (GRAS) status for NR chloride (NIAGEN) in specific formulations, acknowledged by FDA in a 2015 no-objection letter, though GRAS status does not confer approval for pediatric populations (FDA GRAS Notice 000650).

NAD+ Levels in Adolescence: Is There Any Reason to Supplement?

Probably not, based on current evidence. Healthy adolescents maintain high NAMPT activity and strong NAD+ biosynthesis. A 2021 review in Nature Aging noted that the NAD+ decline associated with aging becomes clinically measurable primarily after the third decade of life (Shade, 2020).

Conditions That Might Theoretically Alter This Picture

A small number of pathological conditions could, in principle, create NAD+ insufficiency even in younger patients:

1. NAMPT deficiency or rare inborn errors of NAD+ metabolism. These are exceedingly rare. Diagnosis requires metabolomics testing, not a clinical assumption.
2. Mitochondrial disease. Some mitochondrial disorders reduce NAD+/NADH ratios. Nicotinamide supplementation has been explored in specific contexts, though NMN or NR specifically have not been formally tested in pediatric mitochondrial disease in RCTs.
3. Inflammatory bowel disease or severe malabsorptive states. Chronic inflammation suppresses NAMPT. One small study found reduced NAD+ in adults with active Crohn's disease, though no therapeutic trial with NMN or NR exists in this population (Houtkooper et al., 2010).

Even in these scenarios, any use in an adolescent would be experimental and would require ethics board oversight.

The Lifestyle Confounders

Before attributing any perceived benefit to a supplement, clinicians should assess whether a teen's diet, sleep, and exercise status are optimized. Dietary tryptophan, niacin (vitamin B3), and green vegetables all contribute to endogenous NAD+ synthesis. A 2018 analysis in Cell Reports found that aerobic exercise increased skeletal muscle NAD+ and SIRT1 activity in sedentary adults without any supplementation (Canto et al., 2010, foundational reference). Sleep restriction, which is highly prevalent in adolescents, reduces NAMPT expression. Addressing these inputs costs nothing and carries no safety risk.

Transitioning to Adult Care at Age 18: A Clinical Framework

The transition from pediatric or adolescent care to adult care is a structured process, not a birthday-triggered automatic continuation of whatever regimen the patient arrived with. For any patient who has been using NMN or NR during adolescence, age 18 should trigger a formal reassessment using the following framework.

Step 1: Document the Original Indication

Why was this supplement started? If the answer is "anti-aging" or "energy," that is not a medical indication with an evidence base in any age group, let alone adolescents. The transition visit is the right moment to revisit whether an indication exists at all.

Step 2: Review the Evidence at Adult Age

The adult literature, while modest, is more developed than the adolescent literature. At 18, a patient can be counseled using actual trial data. The Yoshino 2021 trial and the Liao 2021 trial mentioned earlier provide at least some framework for discussing realistic expectations and known short-term safety in adults. The clinician should be transparent that the longest published human NMN trial at the time of writing ran only 12 weeks.

Step 3: Assess for Adult-Appropriate Dosing

Adult NMN trials have used doses ranging from 250 mg/day (Yoshino, 2021) to 1,200 mg/day (HUJI trial, NCT04514809). Adult NR trials have used 1,000 to 2,000 mg/day. No dose-finding study exists for transitioning adolescents. A conservative approach is to start at the lower end of the adult studied range, typically NMN 250 to 500 mg/day or NR 300 to 1,000 mg/day, and reassess after 8 to 12 weeks.

Step 4: Order Baseline Labs

At minimum, obtain:

• Comprehensive metabolic panel (liver function, creatinine, electrolytes)
• Fasting glucose and HbA1c if any metabolic risk factors are present
• Lipid panel
• CBC

These are the parameters monitored in the existing adult safety trials and provide a baseline if any concern arises.

Step 5: Set a Clear Reassessment Timeline

Adult guidelines for dietary supplement use generally recommend reassessment at 3-month intervals for any supplement without established long-term safety data. The Endocrine Society's 2023 clinical practice guidance on metabolic health, while not NMN-specific, supports a structured approach to supplement monitoring in metabolic contexts (Endocrine Society Clinical Practice Guidelines).

Step 6: Discuss Alternatives With Established Evidence

If the underlying goal is metabolic health, insulin sensitivity, or energy, interventions with substantially stronger evidence should be discussed. Structured aerobic exercise for 150 minutes per week improves insulin sensitivity with effect sizes comparable to or exceeding those seen in the Yoshino 2021 NMN trial. Caloric restriction and Mediterranean-pattern diets have decades of evidence behind them. These are appropriate conversations to have at the transition visit.

Safety Considerations Specific to the Adolescent-to-Adult Transition Period

GI Effects

The most consistently reported adverse effect of NMN and NR in adult trials is mild gastrointestinal discomfort, including nausea, bloating, and loose stools. These effects are typically dose-dependent and self-limiting. In the Liao 2021 trial, 8.3% of participants on NMN 300 mg/day reported mild GI symptoms versus 3% on placebo.

Sirtuin and Sex Hormone Interactions

Sirtuins (SIRT1 through SIRT7), activated downstream of elevated NAD+, modulate reproductive hormone signaling. SIRT1 interacts with estrogen receptor alpha and androgen receptor pathways. Adolescence is precisely the period of maximal hormonal activation. No human trial has measured sirtuin-hormone interactions in this age group following NMN or NR supplementation. This gap does not prove harm. It prevents any informed statement about safety.

Methylation Demand

NAD+ metabolism produces nicotinamide as a byproduct. Nicotinamide is methylated by NNMT (nicotinamide N-methyltransferase) using S-adenosylmethionine (SAM) as the methyl donor. High-dose NMN or NR could theoretically increase methyl group demand. In adults, this appears to be a minor concern at doses below 1,000 mg/day, but no data exist for adolescents whose methylation capacity may differ (Mehmel et al., 2020).

Drug Interactions

Adolescents with chronic conditions may be taking medications whose metabolism overlaps with NAD+ pathways. PARP inhibitors (used in some oncology contexts) directly interact with NAD+ availability. Any teen on chemotherapy or immunomodulatory therapy should not take NMN or NR without explicit oncology or rheumatology clearance.

What Parents and Adolescent Patients Are Typically Asking

Parents seeking NAD+ precursors for their adolescent children most often cite concerns about athletic performance, focus, fatigue, or early metabolic optimization. Each of these deserves a direct response.

Athletic performance. No trial has shown NMN or NR to improve exercise performance in any age group. The one trial most relevant to exercise physiology, Elhassan et al. (2019, N=12, NR 1,000 mg/day for 6 weeks), found no significant change in aerobic capacity, muscle strength, or body composition in healthy older men (Elhassan et al., 2019).

Cognitive focus. No published RCT has measured cognitive outcomes in humans following NMN or NR supplementation.

Fatigue. Fatigue in adolescents has a long differential diagnosis that includes iron deficiency, thyroid dysfunction, depression, sleep disorder, and inadequate caloric intake. Attributing fatigue to NAD+ decline in a 14-year-old is not clinically supported.

Early metabolic optimization. This is a reasonable long-term interest but not one that requires NMN or NR at age 12 to 17. Foundational lifestyle habits, built during adolescence, have far more durable metabolic effects than any supplement studied to date.

Monitoring Recommendations After the Transition Visit

Once a patient turns 18 and a clinician decides, after full informed consent, to continue or initiate NMN or NR, the following monitoring schedule aligns with the approach used in published adult safety trials:

| Timepoint | Labs | Clinical | |---|---|---| | Baseline | CMP, CBC, fasting glucose, HbA1c, lipids | Weight, BP, symptom review | | 8 to 12 weeks | CMP, fasting glucose | Symptom and GI review | | 6 months | CMP, CBC, lipids | Weight, BP, efficacy discussion | | Annually | Full panel above | Re-evaluate indication |

Discontinuation should be considered if liver enzymes rise above 3x the upper limit of normal, if unexplained GI symptoms persist beyond 4 weeks, or if no subjective or objective benefit is documented at 6 months.

Key Gaps That Future Research Needs to Address

The field needs, at minimum:

• A dose-finding pharmacokinetic study of NMN and NR in patients ages 14 to 18
• A 6-month safety trial with prespecified monitoring of hormonal and metabolic parameters in adolescents
• Long-term follow-up data on adults who began NAD+ supplementation before age 20

Until those data exist, any clinical decision to use these compounds in patients under 18 is made without a pediatric evidence base. That fact should be communicated clearly at every clinical encounter, and it becomes especially relevant at the transition visit when the patient and their new adult-care team are formalizing a long-term plan.

The FDA's 2022 advisory on NMN's regulatory classification adds further reason for caution. Clinicians who recommend NMN to any patient, adolescent or adult, should document their rationale and be prepared to revisit that decision as the regulatory and evidence field changes.

At the 18-year transition visit, document the original indication, consent the patient using current adult trial data, order baseline labs, start at the low end of studied adult doses (NMN 250 mg/day or NR 300 mg/day), and schedule an 8-week follow-up to assess tolerability and whether any measurable endpoint is being tracked.